Navigation Links
Response Genetics Reports Second Quarter 2007 Financial Results
Date:8/19/2007

dividends 6,097,579 -

Deferred revenue, net of current

portion 3,320,000 1,621,489

Total liabilities 13,762,049 8,811,527

Commitments and contingencies

Stockholders' equity (deficit)

Series B Convertible Preferred

Stock, $0.01 par value; 1,038,048

issued and outstanding (liquidation

preference of $9 per share, or

$9,342,432 plus accrued but unpaid

dividends) at December 31, 2006 10,380 -

Series A Junior Convertible

Preferred Stock, $0.01 par value;

500,000 issued and outstanding

(liquidation preference of $5 per

share, or $2,500,000) at December

31, 2006 5,000 -

Common stock, $0.01 par value;

20,000,000 and 50,000,000 shares

authorized; 2,726,320 and

10,239,256 shares issued and

outstanding 27,263 102,393

Additional paid-in capital 9,722,273 34,311,892

Accumulated deficit (15,267,284) (18,509,649)

Accumulated other comprehensive

income (loss) - (4,208)

Total stockholders' (deficit)

equity (5,502,368) 15,900,428

Total liabilities and stockholders'

(deficit) equity $ 8,259,681 $ 24,711,955

RESPONSE GENETICS, INC.

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

Three Months Ended Six Months

June 30, Ended June 30,

2006 2007 2006 2007

Revenue $ 738,150 $ 1,495,618 $ 2,007,125
'/>"/>

SOURCE Response Genetics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system
2. FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses
3. IT critical in pandemic response, but many are not paying attention
4. Quick response manufacturing and biotech
5. Wisconsin court affirms damages in Innogenetics, Abbott patent case
6. Third Wave licenses Innogenetics tech to settle lawsuit
7. Symposium examines the effect of race on genetics and disease
8. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
9. Sonic Foundry reports GAAP loss as Q2 revenues rise
10. Fiserv reports $113.5 million in Q1 profit
11. Third Wave reports net loss of $18.9M for 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... /CNW/ - A new national Labour Market Information (LMI) ... profiles of new graduates entering the biotech sector. The ... for New Grads in Biotech," is sponsored in part ... (Rx&D) and features data collected from new graduates that ... from 2013 to 2015. Among the interesting ...
(Date:3/30/2015)... N.J. , March 30, 2015  Naldemedine, ... under development by Shionogi & Co., Ltd., met ... III study (COMPOSE I) for the treatment of ... non-cancer pain receiving opioid therapy. Study results showed ... statistically significantly improved the frequency of spontaneous bowel ...
(Date:3/29/2015)... , March 29, 2015 Caris ... important study data showing the presence of ... gynecologic cancer samples. Using Caris Molecular Intelligence®, ... researchers identified expression of programmed cell death ... of histology while its ligand (PD-L1) expression ...
(Date:3/27/2015)... March 27, 2015  Neogen Corporation (NASDAQ: NEOG ... a prearranged trading plan in accordance with Securities and ... and CEO of Neogen Corporation, is a minority owner ... common stock. Herbert does not have control ... The filing is only for a portion of the ...
Breaking Biology Technology:New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 2New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 3New Report on Graduates in Canadian Biotech Industry Sheds Light on Hiring Practices 4Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Neogen CEO adopts 10b5-1 Trading Plan 2
... presented at Coalition,s Annual Meeting, FREMONT, Calif., Sept. ... diagnostics company, announced today that a,team of scientists at ... Research Award" at the Annual General Meeting of the,PAD ... and Dr. Eric T.,Fung, Chief Scientific Officer at Vermillion, ...
... FREMONT, Calif., Sept. 8 Zosano Pharma, ... transdermal,delivery technology, today announced that Gail Schulze has ... also announced several recent,appointments to the Zosano leadership ... John M. Vuko, executive vice president and,chief financial ...
... 8 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) ... in a Phase 2 clinical trial using intravenous,administration ... patients with advanced head and neck cancers. The ... Therapy & Research Center,(CTRC) at The University of ...
Cached Biology Technology:Vermillion and Stanford Scientists Receive 'Best Research Award' From the PAD Coalition 2Vermillion and Stanford Scientists Receive 'Best Research Award' From the PAD Coalition 3Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 2Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 3Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO 4Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 2Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin 3
(Date:3/24/2015)... GARDENS, Fla. , March 24, 2015 /PRNewswire/ ... identity management solutions, today announced that its U.are.U ... clothing accessory retailer Goorin Bros . to ... Crossmatch biometrics-based solution secures access to the POS ... the increased risk of data breaches. ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... an old idea about how species can originate. Morphologically ... have speculated that these "morphs" could be the raw ... individuals within the same population could eventually evolve into ... researchers at the University of California, Santa Cruz, supports ...
... arranging themselves in specific patterns on surfaces. This ability ... are dependend on the assembly of ordered structures on ... to predict or control the result of such processes. ... Hermann, a physicist from the Center for Nanoscience (CeNS) ...
... threatened forests are far more sensitive to damage to ... An analysis of monkeys living in Tanzania,s Udzungwa ... as human activity, on species numbers is felt in ... also found that the health of monkey populations is ...
Cached Biology News:Evolutionary game of rock-paper-scissors may lead to new species 2Evolutionary game of rock-paper-scissors may lead to new species 3Evolutionary game of rock-paper-scissors may lead to new species 4When molecules leave tire tracks 2When molecules leave tire tracks 3
... animal infusion kits reduce the time and ... while providing sterile equipment to reduce the ... you need for one animal, including swivel, ... will be cut to the exact lengths ...
... new chapter to a 40-year ... 7890A GC gives you everything ... lab to the next level ... including advanced separation capabilities, powerful ...
... often call for critical, but time-consuming ... refines siRNA transfection protocols resulting in ... can be used to efficiently transfect ... without increased cytotoxicity. From start ...
... In Situ Assay Kit is a fluorescent-based ... cells undergoing apoptosis. The kit is for ... diagnostic or therapeutic procedures. CHEMICON®s CaspaTag™ Pan-Caspase ... approach to detect active caspases. The methodology ...
Biology Products: